Intraocular inflammation secondary to intravitreal brolucizumab treated successfully with Sub-Tenon triamcinolone: A case report

• Published in: American journal of ophthalmology case reports Vol. 25; p. 101289
• Main Authors: Kurup, Shree K., Tabbaa, Tarek, Echegaray, Jose J., Oliver, Armando L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2022; Elsevier
• Subjects: Age-related macular degeneration; Brolucizumab; Case Report; Intraocular inflammation; Sub-Tenon triamcinolone; Uveitis; Sub-Tenon triamcinolone; Age-related macular degeneration; Brolucizumab; Intraocular inflammation; Uveitis
• ISSN: 2451-9936; 2451-9936
• DOI: 10.1016/j.ajoc.2022.101289

To report on a case of successful treatment of intraocular inflammation (IOI) secondary to brolucizumab intravitreal injection that responded to a single sub-Tenon injection of triamcinolone. An 81-year-old female with a longstanding history of exudative age-related macular degeneration (AMD) was unresponsive to various regimens of anti-VEGF injections. Her AMD was treated with one intravitreal injection of brolucizumab (6mg/0.05ml) into the right eye. On a follow-up visit, she had a new-onset conjunctival injection, with anterior chamber and vitreous inflammation, in the right eye, which was diagnosed as non-granulomatous iridocyclitis. The patient was treated with one posterior sub-Tenon injection of triamcinolone (40mg/ml) into the right eye. Subsequently, there was a durable resolution of inflammation, and her vision improved along with the resolution of her exudation. This case suggests that some brolucizumab-related IOI episodes may be treated with posterior sub-Tenon triamcinolone. Further studies may serve to elucidate the role of sub-Tenon triamcinolone in brolucizumab-associated IOI.